# Traws Pharma, Inc.: financial statements, quarterly

TRAW · Nasdaq · CIK 1130598 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/traw.md) · [Financials](/companies/traw/financials.md) · [Filings](/companies/traw/filings.md) · [Insiders](/companies/traw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/traw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001558370-24-015752.md) | [0.1 d](/filings/0001558370-25-004165.md) | [0.1](/filings/0001558370-25-007872.md) | [0.1](/filings/0001558370-25-011469.md) | [0.1](/filings/0001558370-24-015752.md) | [0.1 d](/filings/0001104659-26-043832.md) | [0.1](/filings/0001104659-26-061779.md) | [2.7](/filings/0001104659-26-097261.md) | [0.0 d](/filings/0001104659-25-110845.md) | [0.0 d](/filings/0001104659-26-043832.md) | not reported | not reported |
| Research and development | $m | [2.5](/filings/0001558370-23-019049.md) | [2.4 d](/filings/0001558370-24-004525.md) | [1.9](/filings/0001558370-24-008326.md) | not reported | not reported | not reported | [2.5](/filings/0001104659-26-061779.md) | [2.3](/filings/0001104659-26-097261.md) | not reported | not reported | [4.9](/filings/0001104659-26-061779.md) | [1.1](/filings/0001104659-26-097261.md) |
| Operating income | $m | [(5.1)](/filings/0001558370-24-015752.md) | [(4.5) d](/filings/0001558370-25-004165.md) | [(5.2)](/filings/0001558370-25-007872.md) | [(123)](/filings/0001558370-25-011469.md) | [(8.5)](/filings/0001104659-25-110845.md) | [(5.3) d](/filings/0001104659-26-043832.md) | [(5.2)](/filings/0001104659-26-061779.md) | [(1.2)](/filings/0001104659-26-097261.md) | [(4.1)](/filings/0001104659-25-110845.md) | [(7.4) d](/filings/0001104659-26-043832.md) | [(6.9)](/filings/0001104659-26-061779.md) | [(3.2)](/filings/0001104659-26-097261.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(4.7)](/filings/0001558370-24-015752.md) | [(4.2) d](/filings/0001558370-25-004165.md) | [(5.0)](/filings/0001558370-25-007872.md) | [(123)](/filings/0001558370-25-011469.md) | [(8.5)](/filings/0001104659-25-110845.md) | [(29.9) d](/filings/0001104659-26-043832.md) | [21.5](/filings/0001104659-26-061779.md) | [(0.9)](/filings/0001104659-26-097261.md) | [(4.0)](/filings/0001104659-25-110845.md) | [(7.4) d](/filings/0001104659-26-043832.md) | [(7.1)](/filings/0001104659-26-061779.md) | [(3.1)](/filings/0001104659-26-097261.md) |
| Diluted EPS | $ per share | [(5.64)](/filings/0001558370-24-015752.md) | not reported | [(5.92)](/filings/0001558370-25-007872.md) | [(20.52)](/filings/0001558370-25-011469.md) | [(1.49)](/filings/0001104659-25-110845.md) | not reported | [2.09](/filings/0001104659-26-061779.md) | [(0.11)](/filings/0001104659-26-097261.md) | [(0.34)](/filings/0001104659-25-110845.md) | not reported | [(0.53)](/filings/0001104659-26-061779.md) | [(0.16)](/filings/0001104659-26-097261.md) |
| Basic EPS | $ per share | [(5.64)](/filings/0001558370-24-015752.md) | not reported | [(5.92)](/filings/0001558370-25-007872.md) | [(20.52)](/filings/0001558370-25-011469.md) | [(1.49)](/filings/0001104659-25-110845.md) | not reported | [2.17](/filings/0001104659-26-061779.md) | [(0.11)](/filings/0001104659-26-097261.md) | [(0.34)](/filings/0001104659-25-110845.md) | not reported | [(0.53)](/filings/0001104659-26-061779.md) | [(0.16)](/filings/0001104659-26-097261.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [20.6](/filings/0001558370-24-004525.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [27.0](/filings/0001558370-23-019049.md) | [22.7](/filings/0001558370-25-004165.md) | [18.2](/filings/0001558370-24-008326.md) | [18.7](/filings/0001558370-24-012279.md) | [8.9](/filings/0001558370-24-015752.md) | [25.0](/filings/0001104659-26-043832.md) | [18.9](/filings/0001558370-25-007872.md) | [15.4](/filings/0001558370-25-011469.md) | [9.6](/filings/0001104659-25-110845.md) | [8.0](/filings/0001104659-26-097261.md) | [5.7](/filings/0001104659-26-061779.md) | [9.0](/filings/0001104659-26-097261.md) |
| Total assets | $m | [27.0](/filings/0001558370-23-019049.md) | [22.7](/filings/0001558370-25-004165.md) | [18.2](/filings/0001558370-24-008326.md) | [18.7](/filings/0001558370-24-012279.md) | [8.9](/filings/0001558370-24-015752.md) | [25.0](/filings/0001104659-26-043832.md) | [19.1](/filings/0001558370-25-007872.md) | [15.6](/filings/0001558370-25-011469.md) | [12.4](/filings/0001104659-25-110845.md) | [10.6](/filings/0001104659-26-097261.md) | [8.2](/filings/0001104659-26-061779.md) | [11.5](/filings/0001104659-26-097261.md) |
| Current liabilities | $m | [9.7](/filings/0001558370-23-019049.md) | [9.2](/filings/0001558370-25-004165.md) | [9.4](/filings/0001558370-24-008326.md) | [9.9](/filings/0001558370-24-012279.md) | [8.3](/filings/0001558370-24-015752.md) | [11.5](/filings/0001104659-26-043832.md) | [10.4](/filings/0001558370-25-007872.md) | [7.4](/filings/0001558370-25-011469.md) | [7.9](/filings/0001104659-25-110845.md) | [11.1](/filings/0001104659-26-097261.md) | [13.2](/filings/0001104659-26-061779.md) | [9.7](/filings/0001104659-26-097261.md) |
| Total liabilities | $m | [12.5](/filings/0001558370-23-019049.md) | [12.0](/filings/0001558370-25-004165.md) | [12.2](/filings/0001558370-24-008326.md) | [12.6](/filings/0001558370-24-012279.md) | [11.0](/filings/0001558370-24-015752.md) | [56.6](/filings/0001104659-26-043832.md) | [13.1](/filings/0001558370-25-007872.md) | [7.4](/filings/0001558370-25-011469.md) | [7.9](/filings/0001104659-25-110845.md) | [11.2](/filings/0001104659-26-097261.md) | [13.5](/filings/0001104659-26-061779.md) | [9.8](/filings/0001104659-26-097261.md) |
| Shareholders' equity | $m | [14.5](/filings/0001558370-24-015752.md) | [10.7](/filings/0001104659-26-043832.md) | [6.0](/filings/0001558370-25-011469.md) | [(106)](/filings/0001104659-25-110845.md) | [(2.0)](/filings/0001104659-25-110845.md) | [(31.6)](/filings/0001104659-26-097261.md) | [6.0](/filings/0001104659-26-097261.md) | [8.3](/filings/0001104659-26-097261.md) | [4.5](/filings/0001104659-25-110845.md) | [(0.6)](/filings/0001104659-26-097261.md) | [(5.3)](/filings/0001104659-26-097261.md) | [1.7](/filings/0001104659-26-097261.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.5) d](/filings/0001558370-24-015752.md) | [(4.4) d](/filings/0001558370-25-004165.md) | [(4.4)](/filings/0001558370-25-007872.md) | [(9.9) d](/filings/0001558370-25-011469.md) | [(11.5) d](/filings/0001104659-25-110845.md) | [(4.0) d](/filings/0001104659-26-043832.md) | [(5.4)](/filings/0001104659-26-061779.md) | [(6.0) d](/filings/0001104659-26-097261.md) | [(4.0) d](/filings/0001104659-25-110845.md) | [(2.8) d](/filings/0001104659-26-043832.md) | [(2.6)](/filings/0001104659-26-061779.md) | [(7.5) d](/filings/0001104659-26-097261.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001558370-25-004165.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-110845.md) | [0.0 d](/filings/0001104659-26-043832.md) | not reported | not reported | not reported | [0.0 d](/filings/0001104659-26-043832.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.9](/filings/0001558370-23-019049.md) | [21.0](/filings/0001558370-24-008326.md) | [21.0](/filings/0001558370-24-012279.md) | [0.8](/filings/0001558370-24-015752.md) | [0.8](/filings/0001558370-25-007872.md) | [1.0](/filings/0001558370-25-011469.md) | [1.0](/filings/0001104659-25-110845.md) | [7.2](/filings/0001104659-26-061779.md) | [5.8](/filings/0001104659-26-097261.md) | [8.8](/filings/0001104659-25-110845.md) | [10.6](/filings/0001104659-26-061779.md) | [15.9](/filings/0001104659-26-097261.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,368,277 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097261.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.